Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

rupitasertib (DIACC3010)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

EMD Serono, Evexta Bio

Drug class:

AKT inhibitor, p70S6K inhibitor, AKT1 inhibitor, AKT3 inhibitor

Related drugs:

‹

›

ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3	DIACC3010 Sensitive: C3 – Early Trials DIACC3010 Sensitive : C3
AKT1 E17K + HR positive	HER2 Negative Breast Cancer	AKT1 E17K + HR positive	HER2 Negative Breast Cancer	DIACC3010 Sensitive: C4 – Case Studies DIACC3010 Sensitive : C4	DIACC3010 Sensitive: C4 – Case Studies DIACC3010 Sensitive : C4
PIK3CA H1047R + HER-2 amplification	Breast Cancer	PIK3CA H1047R + HER-2 amplification	Breast Cancer	trastuzumab + DIACC3010 Sensitive: C4 – Case Studies trastuzumab + DIACC3010 Sensitive : C4	trastuzumab + DIACC3010 Sensitive: C4 – Case Studies trastuzumab + DIACC3010 Sensitive : C4
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	trastuzumab + DIACC3010 Sensitive: D – Preclinical trastuzumab + DIACC3010 Sensitive : D	trastuzumab + DIACC3010 Sensitive: D – Preclinical trastuzumab + DIACC3010 Sensitive : D
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	DIACC3010 Sensitive: D – Preclinical DIACC3010 Sensitive : D	DIACC3010 Sensitive: D – Preclinical DIACC3010 Sensitive : D